Harvard Apparatus Regenerative Technology (HRGN) AI Stock Analysis

• Market Cap: $27.95M
• Dividend Yield: N/A
• Average Volume (3M): 1.13K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.04
• Revenue Growth: 216.17%
• EPS Growth: 29.97%
• Country: US
• Employees: 8
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.11
• Shares Outstanding: 17,580,744
• 10 Day Avg. Volume: 797
• 30 Day Avg. Volume: 1,125
• PEG Ratio: 0.23
• Price to Book (P/B): 28.75
• Price to Sales (P/S): 43.17
• P/FCF Ratio: -7.94
• Enterprise Value/Market Cap: 0.95
• Enterprise Value/Revenue: 120.93
• Enterprise Value/Gross Profit: -62.02
• Enterprise Value/Ebitda: -3.87
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $1.50 ▼(-17.58% Downside)
• Action: Reiterated Date: 03/20/26
• Date: Action: Reiterated 03/20/26

The score is primarily constrained by weak financial performance (no revenue, sustained losses, and ongoing cash burn), with technicals also slightly negative (below key moving averages and negative MACD). A modest positive comes from the recent capital raise improving near-term funding, but valuation remains unattractive given losses (negative P/E) and no dividend support.

Positive Factors

Low leverage / stronger equity base

A low absolute debt load relative to equity gives the company a structurally low leverage profile. That reduces near‑term solvency risk and preserves optionality for R&D and strategic moves, providing a firmer balance‑sheet base while commercialization is pursued.

Negative Factors

Zero revenue / persistent operating losses

The company remains pre‑commercial with no reported revenue and sustained large operating losses. Over the medium term this prevents internal funding of development, increases execution risk for commercialization, and forces dependence on external financing to sustain operations.

Harvard Apparatus Regenerative Technology Business Overview & Revenue Model

Company Description

Harvard Apparatus Regenerative Technology Inc., a clinical-stage biotechnology company, focuses on developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma, or birth d...

Read more

Harvard Apparatus Regenerative Technology Inc., a clinical-stage biotechnology company, focuses on developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma, or birth d...

How the Company Makes Money

null...

Harvard Apparatus Regenerative Technology Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Mar 2024	Dec 2022	Mar 2022
Income Statement
Total Revenue	704.00K	0.00	0.00	0.00	0.00
Gross Profit	58.00K	-270.00K	-24.00K	0.00	0.00
EBITDA	-6.76M	-8.16M	-9.09M	-5.92M	-8.89M
Net Income	-6.87M	-7.73M	-9.02M	-6.07M	-7.98M
Balance Sheet
Total Assets	2.68M	4.44M	2.61M	2.40M	1.87M
Cash, Cash Equivalents and Short-Term Investments	1.35M	2.49M	432.00K	1.24M	1.24M
Total Debt	199.00K	294.00K	48.00K	147.00K	169.00K
Total Liabilities	1.62M	1.22M	968.00K	1.41M	4.89M
Stockholders Equity	1.06M	3.22M	1.65M	989.00K	-3.03M
Cash Flow
Free Cash Flow	-3.83M	-4.85M	-6.95M	-5.11M	-2.63M
Operating Cash Flow	-3.83M	-4.85M	-6.94M	-5.11M	-2.63M
Investing Cash Flow	0.00	0.00	-11.00K	-5.00K	0.00
Financing Cash Flow	2.70M	6.91M	6.14M	5.06M	2.84M

Harvard Apparatus Regenerative Technology Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.82
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HRGN, the sentiment is Negative. The current price of 1.82 is above the 20-day moving average (MA) of 1.67, above the 50-day MA of 1.72, and above the 200-day MA of 1.75, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 29.90 is Positive, neither overbought nor oversold. The STOCH value of 39.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HRGN.

Harvard Apparatus Regenerative Technology Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LSTA	59 Neutral	$45.25M	-0.97	-84.39%	―	―	15.32%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SABS	50 Neutral	$191.07M	5.44	-21.16%	―	-92.42%	62.37%
LGVN	50 Neutral	$26.99M	-0.39	-119.92%	―	-22.41%	78.88%
MBRX	46 Neutral	$13.98M	-1.17	―	―	―	79.31%
HRGN	45 Neutral	$27.95M	-4.42	-344.15%	―	216.17%	29.97%
PULM	43 Neutral	$4.38M	-1.58	-79.47%	―	-99.97%	35.59%

Harvard Apparatus Regenerative Technology Corporate Events